Actelion receives US FDA approval of Opsumit (macitentan) for the treatment of pulmonary arterial hypertension

Actelion Ltd (SIX: ATLN) announced today that the United States Food and Drug Administration (FDA) has approved the use of the orally available endothelin receptor antagonist Opsumit� (macitentan) 10 mg once daily for the treatment of pulmonary arterial hypertension (PAH) to delay disease progression. Opsumit is indicated for the treatment of pulmonary arterial hypertension (PAH, WHO Group I) to delay disease progression...

Source: http://feedproxy.google.com/~r/mnt/healthnews/~3/W1fQr8_ReLY/267719.php

news auto sport medical